LEADER 01073nam0-22003731i-450- 001 990003997970403321 005 20061027101157.0 010 $a0-521-55302-4 035 $a000399797 035 $aFED01000399797 035 $a(Aleph)000399797FED01 035 $a000399797 100 $a20040209d1999----km-y0itay50------ba 101 1 $aeng 102 $aUS 105 $aa---a---001yy 200 1 $aLevy processes and infinitely divisible distribution$fKen-Iti Sato 210 $aCambridge$cCambridge University press$dc1999 215 $axii, 486 p.$d24 cm 225 1 $aCambridge studies in advanced mathematics$v68 610 0 $aProcessi auto-similari 610 0 $aTeoria della probabilità 676 $a519.2$v21 700 1$aSato,$bKenichi$f<1934- >$0151159 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990003997970403321 952 $aC-43-(68$b17237$fMA1 959 $aMA1 962 $a60-02 962 $a60G18 962 $a60G31 996 $aLevy processes and infinitely divisible distribution$9471625 997 $aUNINA LEADER 01010oam 2200325zu 450 001 996248020103316 005 20210807002856.0 035 $a(CKB)1000000000548232 035 $a(SSID)ssj0000084017 035 $a(PQKBManifestationID)11988169 035 $a(PQKBTitleCode)TC0000084017 035 $a(PQKBWorkID)10163994 035 $a(PQKB)22496713 035 $a(EXLCZ)991000000000548232 100 $a20160829d2007 uy 101 0 $aeng 181 $ctxt 182 $cc 183 $acr 200 14$aThe Correspondence, Volume VI: A Supplement with a Composite Index 210 31$a[Place of publication not identified]$cNew York University Press$d2007 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-8147-9426-2 700 $aWhitman$b Walt$0159715 702 $aMiller$b Edwin 801 0$bPQKB 906 $aBOOK 912 $a996248020103316 996 $aThe Correspondence, Volume VI: A Supplement with a Composite Index$92399559 997 $aUNISA LEADER 10689nam 22004453 450 001 9910512165003321 005 20211213080214.0 010 $a9789811627828$b(electronic bk.) 010 $z9789811627811 035 $a(MiAaPQ)EBC6824951 035 $a(Au-PeEL)EBL6824951 035 $a(CKB)20094266200041 035 $a(EXLCZ)9920094266200041 100 $a20211213d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBioSensing, Theranostics, and Medical Devices $eFrom Laboratory to Point-Of-Care Testing 210 1$aSingapore :$cSpringer Singapore Pte. Limited,$d2022. 210 4$d©2022. 215 $a1 online resource (380 pages) 311 08$aPrint version: Borse, Vivek BioSensing, Theranostics, and Medical Devices Singapore : Springer Singapore Pte. Limited,c2022 9789811627811 327 $aIntro -- Contents -- About the Editors -- Chapter 1: Gold Nanoclusters as Emerging Theranostic Interventions for Biomedical Applications -- 1.1 Introduction -- 1.2 Synthesis of AuNCs -- 1.3 Gold Nanoclusters as Biosensors -- 1.4 Gold Nanoclusters as Therapeutics -- 1.5 Conclusions and Future Prospects -- References -- Chapter 2: Advances in Materials, Methods, and Principles of Modern Biosensing Tools -- 2.1 Introduction -- 2.2 Materials for Biosensors -- 2.3 Principles of Biosensing -- 2.3.1 Colorimetric -- 2.3.1.1 Liquid Phase Biosensors -- 2.3.1.2 Paper Biosensors -- 2.3.1.3 Microfluidic Biosensors -- 2.3.1.4 Microfluidic Paper Analytical Devices (?PADs) -- 2.3.2 Colorimetric Assays -- 2.3.3 Chemiresistive Biosensors -- 2.3.4 Electrochemical Biosensors -- 2.3.5 Semiconductor Biosensors -- 2.4 Recent Trends of Biosensing and Device Fabrication -- 2.5 Future of Biosensing -- 2.6 Summary -- References -- Chapter 3: Evolution Towards Theranostics: Basic Principles -- 3.1 Introduction -- 3.2 Basic Principle of Theranostics in POC -- 3.2.1 Fundamental Prospects -- 3.2.2 Components -- 3.2.3 Point-of-Care Devices -- 3.3 Biological Factors Involved in Theranostic Applications -- 3.3.1 Administration of Nanoparticles -- 3.3.1.1 Passive Targeting -- 3.3.1.2 Active Targeting -- 3.3.1.3 Physical Targeting -- 3.3.2 The Journey of Nanoparticles to the Target Sites -- 3.4 Recent Advancements in Theranostics -- 3.5 Advantages of Smart Theranostics Agents Over Conventional Therapy -- 3.5.1 Localized Therapy -- 3.5.2 Multimodality -- 3.5.3 Simultaneous Diagnosis and Therapy -- 3.5.4 Multifunctionality -- 3.5.5 Real-Time Monitoring -- 3.5.6 Immune-Evasion -- 3.6 Challenges for Responsible Development -- 3.6.1 Toxicity -- 3.6.2 Stability -- 3.6.3 Commerciality -- 3.7 Future Perspective -- 3.8 Conclusion -- References. 327 $aChapter 4: Biosensor-Based Point-of-Care Devices: Metabolites and Pulse Oximetry -- 4.1 Introduction -- 4.2 Glucose Measurement at the Point-of-Care -- 4.2.1 Methods of Measurement -- 4.2.2 Summary of Devices -- 4.2.2.1 Glucose Meters for At-Home Care -- 4.2.2.2 Glucose Meters for Clinical Care -- 4.3 Creatinine Measurement at the Point-of-Care -- 4.3.1 Methods of Measurement -- 4.3.2 Summary of Devices -- 4.4 Lipid Measurement at the Point-of-Care -- 4.4.1 Mechanisms of Measurement -- 4.4.2 Summary of Devices -- 4.5 Pulse Oximetry Measurements at the Point-of-Care -- 4.5.1 Methods of Measurement -- 4.5.2 Summary of Devices -- 4.6 Conclusion -- References -- Chapter 5: Biosensor-Based Point-of-Care Devices: Detection of Infectious Diseases and Cancer -- 5.1 Introduction -- 5.2 Pathogen Detection at the Point-of-Care -- 5.2.1 Methods of Detection -- 5.2.2 Summary of Devices -- 5.2.2.1 HIV -- 5.2.2.2 Tuberculosis -- 5.2.2.3 Malaria -- 5.2.2.4 Syphilis -- 5.2.2.5 Chlamydia and Gonorrhea -- 5.3 Cancer Detection at the Point-of-Care -- 5.3.1 Methods of Detection -- 5.3.2 Summary of Devices -- 5.3.2.1 Prostate Cancer -- 5.3.2.2 Colorectal Cancer -- 5.3.2.3 Liver Cancer -- 5.3.2.4 Bladder Cancer -- 5.4 Conclusion -- References -- Chapter 6: Non-invasive Cellular Characterization Using Bioimpedance Sensing -- 6.1 Introduction -- 6.2 Principle -- 6.2.1 Cell-Substrate Impedance -- 6.2.2 Design and Simulation of Sensor Configuration -- 6.3 Bioimpedance Sensor and Impedance Measurement -- 6.3.1 Device Fabrication -- 6.3.2 Cleaning and Surface Modification of the Sensor -- 6.3.3 Experimental Setup -- 6.3.4 Cell Culture and Cell Seeding Inside the Chip -- 6.3.5 Bioimpedance Measurement -- 6.4 Theoretical Analysis -- 6.4.1 Electrical Equivalent Model of the System -- 6.4.1.1 Estimation of Equivalent Model Parameters. 327 $a6.4.1.2 Fragmental Frequency Analysis Method to Extract the Model Parameters -- 6.4.2 Extracting the Single Cell Property from Measurement of Group of Cells -- 6.4.2.1 Maxwell´s Mixture Theory -- 6.4.2.2 Equivalent Electrical Model of Single Cell -- 6.5 Applications -- 6.5.1 Calculation of Equivalent Parameters of HeLa Cells Using Fragmental Frequency Analysis -- 6.5.1.1 Resistance of the PBS Media -- 6.5.1.2 Resistance Rexp -- 6.5.1.3 Coating Capacitance -- 6.5.1.4 Double Layer Capacitance -- 6.5.1.5 Equivalent Parameters of the HeLa Cells -- 6.5.2 Extraction of Single Cell Parameters of HeLa Cells -- 6.6 Summary -- References -- Chapter 7: Research Aspects and Strategies for the Development of Biosensors for Renal Disease Diagnosis -- 7.1 Point-of-Care Devices and their Importance in Renal Diseases Diagnosis -- 7.2 Various Biomarkers for Kidney Disease Diagnosis -- 7.3 Point-of-Care Devices for Kidney Injury Diagnosis -- 7.4 New Avenues in Developing POC for Renal Diseases -- 7.5 Conclusion -- References -- Chapter 8: From Natural to Artificial Biorecognition Elements: From Antibodies to Molecularly Imprinted Polymers -- 8.1 Introduction -- 8.2 Development and Production of Recognition Elements -- 8.2.1 Antibodies -- 8.2.2 APTAMERs -- 8.2.3 Molecularly Imprinted Polymers (MIPs) -- 8.3 Conclusions -- References -- Chapter 9: Design and Development of a Bed-Side Cardiac Health Monitoring Device -- 9.1 Introduction -- 9.1.1 Tissue as a Conductor -- 9.2 Evolution of Bio-Impedance: Impedance Cardiography -- 9.3 Significance of Non-Invasive Recording of Cardiac Parameters -- 9.4 Physiological and Clinical Applications of Impedance Cardiography -- 9.5 Designing an Electrode - Skin Model for Simulation Studies -- 9.5.1 Current Density -- 9.5.2 Resistive Loss -- 9.5.3 Electric Field Displacement -- 9.6 ICG Acquisition -- 9.6.1 Frequency and Current Values. 327 $a9.6.2 ICG Measurement Methods -- 9.7 ICG Device Fabrication -- 9.8 Conclusion -- References -- Chapter 10: Tailoring Multi-Functional 1D or 2D Nanomaterials: An Approach towards Engineering Futuristic Ultrasensitive Platf... -- 10.1 Introduction -- 10.2 1D or 2D Nanomaterials and its Sensing Application -- 10.2.1 1D Nanomaterials -- 10.2.1.1 Nanofibers -- 10.2.1.2 Nanowires -- 10.2.1.3 Nanotubes -- 10.2.1.4 Nanorods -- 10.2.2 2D Nanomaterials -- 10.2.2.1 Graphene -- 10.2.2.2 Transition Metal Dichalcogenides -- 10.3 Functionalization Routes towards Microbial Detection -- 10.4 1D or 2D Nanomaterials in Nano/Micro-Gap Based Sensing Devices -- 10.4.1 Planar Gaps -- 10.4.2 Planar Gap Based FET Devices -- 10.4.3 Vertical Gap -- 10.5 Sample Preparation -- 10.5.1 Cultures -- 10.5.2 Tissues -- 10.5.3 Blood/Serum/Plasma -- 10.6 Extraction of Biological Molecules for Molecular Detection -- 10.6.1 Nucleic Acid Extraction -- 10.6.2 Protein Extraction -- 10.6.3 Automated Nucleic Acid Extraction Methods -- 10.7 Fluid Kinetics for Detection Systems -- 10.8 1D or 2D Material Based Optical Detection of Microbial Strains -- 10.8.1 Fluorescent Biosensor -- 10.8.2 FRET-Based Biosensors -- 10.8.3 Raman Based Sensor -- 10.8.4 DNA Based Sensor -- 10.9 Summary and Future Work -- References -- Chapter 11: Clinical Validation of the Medical Devices: A General Prospective -- 11.1 Introduction -- 11.2 What Is Clinical Evaluation? -- 11.2.1 Definition -- 11.2.2 Pre-Clinical Evaluation -- 11.3 Needs of Clinical Evaluation of Medical Devices -- 11.4 Type of Clinical Evaluation -- 11.4.1 Clinical Investigation -- 11.4.2 By Literature Way -- 11.5 Clinical Validation According to the Type of Devices -- 11.5.1 Clinical Validation -- 11.5.2 Process Validation -- 11.5.3 Revalidation -- 11.5.4 Design Validation -- 11.6 Clinical Validation for each Class of Medical Devices. 327 $a11.7 Clinical and Analytical Validations of Biosensors Based IVDs -- 11.8 The Regulatory Perspective of the Medical Device in Consideration with Clinical Validation -- 11.8.1 Medical Device Rules (MDR)-2017, India -- 11.8.2 Food and Drug Administration USA -- 11.8.3 Medical Devices Clinical Validation Process in EU -- 11.8.4 Clinical Confirmatory Process in Australia -- 11.8.5 Medical Devices Clinical Validation in China -- 11.9 Conclusions -- References -- Chapter 12: Dried Blood Patterns for Diagnosis of Non-Communicable and Infectious Diseases -- 12.1 Introduction -- 12.2 Whole Blood and its Physical Properties -- 12.3 Physics of Pattern Formation -- 12.4 Factors Affecting the Pattern Formation -- 12.5 Disease Diagnosis Using the Dried Pattern of Blood Plasma and Serum -- 12.6 Disease Diagnosis Using the Dried Pattern of Whole Blood -- 12.7 Challenges and Future Outlook -- References -- Chapter 13: Theranostics: Principles, Materials, and Technical Advancements -- 13.1 Introduction to Principles of Theranostics -- 13.2 Materials for Cancer Theranostics -- 13.2.1 Gold-Based Nanosystems -- 13.2.2 Iron Oxide-Based Nanosystems -- 13.2.3 Other Metallic Nanosystems -- 13.2.4 Carbon-Based Nanosystems -- 13.2.5 Silica-Based Nanosystems -- 13.2.6 Quantum Dots-Based Nanosystems -- 13.2.7 Polymer-Based Nanosystems -- 13.2.8 Lipid-Based Nanosystems -- 13.3 Advanced Theranostic Nanomedicine Platforms for Clinical Applications -- 13.3.1 Photodynamic and Photothermal Therapy -- 13.3.2 Imaging -- 13.3.3 Nanobiosensors -- 13.3.4 Magnetic Hyperthermia -- 13.3.5 Multimodal Image Guided Therapy -- 13.3.6 Treatment of Cardiovascular Diseases -- 13.3.7 Treatment of Central Nervous System Related Diseases -- 13.4 Commercialization and Translational Challenges of Theranostic Nanosystems -- 13.5 Conclusion -- References. 327 $aChapter 14: Nanotheranostics: Nanoparticles Applications, Perspectives, and Challenges. 608 $aElectronic books. 700 $aBorse$b Vivek$01070139 701 $aChandra$b Pranjal$01070140 701 $aSrivastava$b Rohit$01063850 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910512165003321 996 $aBioSensing, Theranostics, and Medical Devices$92557974 997 $aUNINA LEADER 02410oam 2200289z- 450 001 9910135518203321 005 20231023175511.0 035 $a(CKB)3790000000000842 035 $a(Perlego)2363055 035 $a(EXLCZ)993790000000000842 100 $a20210326d2013 uy | 101 0 $aita 200 00$aDemocrazia come partecipazione $eLelio Basso e il PSI alle origini della Repubblica 210 $aRoma $cViella$d2011 311 08$a9788883349539 330 8 $aIntellettuale socialista, membro dell'Assemblea Costituente, studioso del marxismo e del pensiero politico, parlamentare della Repubblica, Lelio Basso e? stato anche uomo d'azione e leader di partito. Sulla base di una vasta documentazione d'archivio in buona parte inedita, questo volume racconta la storia del suo rapporto con il PSI dalla Resistenza alla vigilia del 18 aprile 1948, sullo sfondo del conflitto mondiale, dei drammatici scontri sociali del dopoguerra e della divisione del mondo in blocchi.Basso credeva fermamente nelle potenzialita? del PSI, e si adopero? per farne un moderno partito di massa, in grado di guidare uno schieramento progressista alternativo a quello democristiano. Basso era altresi? convinto che la democrazia non potesse ridursi all'esercizio del voto, ma che dovesse continuamente nutrirsi della partecipazione attiva dei lavoratori e dei ceti sociali emarginati, anche se fino ad allora completamente estranei alla politica. Si impegno? pertanto a tradurre in termini pratici tale aspirazione, provando a fare del PSI uno strumento di alfabetizzazione democratica e un luogo per praticare democrazia.Il progetto bassiano venne tuttavia vanificato dallo scontro ideologico della guerra fredda: la politica come educazione alla partecipazione democratica venne sconfitta dalla politica di potenza. Non fu pero? vanificato il contributo dato da questa esperienza alla nascita e allo sviluppo di un moderno sentimento di cittadinanza nel nostro paese. 517 $aDemocrazia come partecipazione 606 $aSocialism$zItaly$xHistory$y20th century 606 $aDemocracy$zItaly$xHistory$y20th century 607 $aItaly$xPolitics and government$y1943-1947 615 0$aSocialism$xHistory 615 0$aDemocracy$xHistory 700 $aRossi$b Emanuele$f1974-$0118014 906 $aBOOK 912 $a9910135518203321 996 $aDemocrazia come partecipazione$92431921 997 $aUNINA